Prothena reported total revenue of $52.7 million for the first nine months of 2026, driven primarily by $50.1 million from license and intellectual property revenue. The company significantly reduced its operating expenses to $62.6 million compared to $200.1 million in the prior year period, resulting in a narrowed net loss. As of September 30, 2026, the company maintained a cash and cash equivalents balance of $271.4 million.
Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher Barrett’s Esophagus test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.
Term
Q3 2026
“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
Derek Maetzold, president and chief executive officer of Castle Biosciences
“Overall, our third-quarter results reflect the strength of our portfolio, consistent execution and continued progress toward our long-term growth objectives. I want to thank the entire Castle team for their dedication, hard work and unwavering commitment to improving patient care.”
Derek Maetzold, president and chief executive officer of Castle Biosciences